ATE415412T1 - Peptide, die atherosklerotische schädigungen binden - Google Patents

Peptide, die atherosklerotische schädigungen binden

Info

Publication number
ATE415412T1
ATE415412T1 AT02772136T AT02772136T ATE415412T1 AT E415412 T1 ATE415412 T1 AT E415412T1 AT 02772136 T AT02772136 T AT 02772136T AT 02772136 T AT02772136 T AT 02772136T AT E415412 T1 ATE415412 T1 AT E415412T1
Authority
AT
Austria
Prior art keywords
peptides
methods
bind
present
atherosclerotic lesions
Prior art date
Application number
AT02772136T
Other languages
English (en)
Inventor
Cheng Liu
Thomas Edgington
Margaret Prescott
Original Assignee
Novartis Pharma Gmbh
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh, Scripps Research Inst filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE415412T1 publication Critical patent/ATE415412T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02772136T 2001-08-10 2002-08-09 Peptide, die atherosklerotische schädigungen binden ATE415412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31150701P 2001-08-10 2001-08-10

Publications (1)

Publication Number Publication Date
ATE415412T1 true ATE415412T1 (de) 2008-12-15

Family

ID=23207200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772136T ATE415412T1 (de) 2001-08-10 2002-08-09 Peptide, die atherosklerotische schädigungen binden

Country Status (8)

Country Link
US (1) US20070264194A1 (de)
EP (1) EP1419173B1 (de)
JP (2) JP2005507244A (de)
AT (1) ATE415412T1 (de)
AU (1) AU2002336959B2 (de)
CA (1) CA2455336A1 (de)
DE (1) DE60230046D1 (de)
WO (1) WO2003014145A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502618A (ja) * 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション 光力学的化合物を用いて脆弱なプラークを検出および治療する方法
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP1793875B9 (de) 2004-06-16 2010-09-08 Affinergy, Inc. Grenzflächenbiomaterialien zur förderung der anhaftung von zielanalyten
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US7531505B2 (en) 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (de) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2203173B1 (de) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Mittel und verfahren zur bekämpfung von muskelleiden
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
EP2421971B1 (de) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonukleotid mit einem inosin zur behandlung von dmd
WO2011065968A1 (en) * 2009-11-30 2011-06-03 The Scripps Research Institute Use of monocyte chemoattractant compounds to treat ocular disorders
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
JP2015524439A (ja) 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
EP2886140A1 (de) * 2013-12-17 2015-06-24 University of Limerick Vorrichtung zur extrakorporalen Behandlung von Blut
EP3556385A4 (de) * 2016-12-15 2020-12-30 Talengen International Limited Verfahren zur verringerung von herzerkrankungen
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US12384831B2 (en) 2018-02-14 2025-08-12 Tatsuya Sawamura Fusion protein and high-density lipoprotein measurement kit using same
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
EP4059523A4 (de) * 2019-11-15 2024-01-03 Osaka University Verstärker-polynukleotid, das auf herzinsuffizienz reagiert, und expressionvektor, der das verstärker-polynukleotid einschliesst
CN117820429B (zh) * 2024-01-11 2024-06-18 中国水产科学研究院南海水产研究所 一种具有inos抑制作用的乌鳢源活性肽

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
EP0580550B1 (de) * 1992-07-21 1997-10-22 Novartis AG Oxamidsäure-Derivate als hypocholesterämische Mittel
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
JPH08507750A (ja) * 1992-12-15 1996-08-20 ザ・ウエルカム・ファウンデーション・リミテッド ジヒドロフォレートレダクターゼを用いる免疫反応試薬
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
PT1157001E (pt) * 1999-03-01 2004-10-29 Pfizer Prod Inc Acidos oxamicos e derivados como ligandos do receptor da tiroide
AU1197001A (en) * 1999-10-29 2001-05-14 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
AU2002303832A1 (en) * 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides

Also Published As

Publication number Publication date
JP2009050275A (ja) 2009-03-12
EP1419173A2 (de) 2004-05-19
JP2005507244A (ja) 2005-03-17
AU2002336959B2 (en) 2006-07-13
WO2003014145A3 (en) 2003-12-04
WO2003014145A2 (en) 2003-02-20
DE60230046D1 (de) 2009-01-08
US20070264194A1 (en) 2007-11-15
CA2455336A1 (en) 2003-02-20
EP1419173B1 (de) 2008-11-26

Similar Documents

Publication Publication Date Title
DE60230046D1 (de) Peptide, die atherosklerotische schädigungen binden
WO2001055355A8 (en) Nucleic acids, proteins, and antibodies
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
SG144925A1 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2008073458A3 (en) Fibrin-binding peptides and conjugates thereof
WO2001055317A8 (en) Nucleic acids, proteins, and antibodies
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
ATE538811T1 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
SE0301987D0 (sv) New polypeptide
ATE445842T1 (de) Nachweis spezifischer nitrierter marker
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
ATE306497T1 (de) Peptid für die diagnose und therapie von tumoren
WO2001055300A8 (en) Nucleic acids, proteins, and antibodies
WO2007068449A3 (de) Molekulare marker für eine tumordiagnose und -therapie
WO2007020405A3 (en) Integrin i-domain binding peptides
GB2415195A (en) Peptides of IRF-1
WO2001055313A8 (en) Nucleic acids, proteins, and antibodies
WO2003060074A3 (en) Novel metastasis suppressor gene on human chromosome 8

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties